Related Experiment Videos
BQ 22-708, a new antihypertensive agent with vasodilator properties
The New Zealand Medical Journal
|March 12, 1980
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Studies in the rat on bucindolol, a new antihypertensive agent with beta-adrenoceptor blocking properties.
Archives internationales de pharmacodynamie et de therapie·1981
Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.
Clinical and experimental pharmacology & physiology·1981
Haemodynamic interactions between alpha- and beta-adrenoceptor antagonists in conscious or anaesthetized rats.
Clinical and experimental pharmacology & physiology·1980
Responsiveness of hypertensive subjects to prazosin.
Clinical and experimental pharmacology & physiology·1980
Profile of a new prazosin congener, BL-5111A. Studies in the rat.
Clinical and experimental pharmacology & physiology·1980
Effects of prazosin on blood pressure and plasma renin activity during onset and withdrawal of action in the anaesthetized rat.
Clinical and experimental pharmacology & physiology·1979
Publicly funded healthcare, social insurance and justice in Aotearoa New Zealand.
The New Zealand medical journal·2026
Drilling a hole to shorten the gap: an Aotearoa New Zealand therapeutic algorithm for status epilepticus in NEUROPA (Madrid, Spain).
The New Zealand medical journal·2026
The impact of New Zealand's 2018 methamphetamine policy on residential contamination.
The New Zealand medical journal·2026
The Deterioration Early Warning System for aged residential care: a feasibility study with qualitative analysis.
The New Zealand medical journal·2026
Hand grip strength and future hospitalisations in Māori and non-Māori New Zealand octogenarians: the LiLACS NZ cohort study.
The New Zealand medical journal·2026
Utilization, tolerability, and perception of medical cannabis use in patients with seizures.
Epilepsy & behavior : E&B·2026
MMP2 sheds Glypican-4 to suppress Slit3-Robo4 signaling and angiogenesis.
Proteoglycan research·2026